TABLE 3.
(a) Summary of baseline characteristics of the CALGB 9633 trial sample and the NCDB sample. (b) Point estimate, standard error, and 95% percentile confidence interval of the causal risk difference between adjuvant chemotherapy and observation based on the CALGB 9633 trial sample and the NCDB sample
| (a) | ||
|---|---|---|
| RCT: CALGB 9633 n = 319 |
OS: NCDB n = 15,379 |
|
| Recurrence (Y), n(%) | 79 (25) | 5060 (33) |
| Treatment (A), n(%) | ||
| Adjuvant chemotherapy | 156 (49) | 4324 (28) |
| Observation | 163 (51) | 11055 (72) |
| Gender (X1), n(%) | ||
| Male | 204 (64) | 8458 (55) |
| Female | 115 (36) | 6921 (45) |
| Age (X2), mean ± SD | 60.83 ± 9.62 | 67.87 ± 10.18 |
| Histology (X3), n(%) | ||
| Squamous | 128 (40) | 5998 (39) |
| Non-squamous | 191 (60) | 9381 (61) |
| Tumor size (X4), mean ± SD | 4.6 ± 2.08 | 4.94 ± 3.04 |
| (b) | |||
|---|---|---|---|
| 95% CI | |||
| Naive | −0.083 | 0.044 | (−0.163, −0.018) |
| IPSW | −0.088 | 0.060 | (−0.211, 0.019) |
| AIPSW | −0.088 | 0.060 | (−0.187, 0.041) |
| AIPSW(S) | −0.106 | 0.068 | (−0.233, 0.020) |
| SBW | −0.090 | 0.057 | (−0.187, 0.017) |
| CW | −0.105 | 0.058 | (−0.221, 0.000) |
| ACW-t(S) | −0.139 | 0.106 | (−0.309, 0.041) |
| ACW-t(SO) | −0.122 | 0.080 | (−0.237, 0.054) |
| ACW-b(S) | −0.174 | 0.098 | (−0.360, −0.044) |
| ACW-b(SO) | −0.172 | 0.088 | (−0.357, −0.050) |